Ann: Director appointments, page-8

Hi All,

The value will come from Dr Elliot’s & Neville Gardiner’s experience.

CSL Behring are focused on blood-based products in multiple diseases, & drug development in Rare Disease particularly.

https://www.cslbehring.com/products

I agree with Sisu, but - Never say never though with potentially branching out, noting that cardiac & metabolic disease as a clinical area of focus, are listed under CSL’s pipeline & this includes DM.

Remembering we are a Diagnostic Development Company, not drug development. Things are also moving quite quickly in this space, although it doesn’t seem so for SH at times.

https://www.csl.com/research-and-development/product-pipeline

I think it’s great that PIQ have attracted new non-exec Directors with such calibre.

Great ANN